Journal of Clinical Oncology, Vol 21, Issue 1
(January), 2003: 28-34
© 2003 American Society for Clinical Oncology
Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998
Christopher I. Li,
Janet R. Daling,
Kathleen E. Malone
From the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.
Address reprint requests to Christopher Li, MD, MPH, Division of Public Health Sciences, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, MP 381, PO Box 19024, Seattle, WA 98109-1024; email: cili{at}fhcrc.org.
Purpose: Between 1987 and 1998, breast cancer incidence rates rose 0.5%/yr in the United States. A question of potential etiologic and clinical importance is whether the hormone receptor status of breast tumors is also changing over time. This is because hormone receptor status may reflect different etiologic pathways and is useful in predicting response to adjuvant therapy and prognosis.
Methods: Age-adjusted, age-specific breast cancer incidence rates by estrogen receptor (ER) and progesterone receptor (PR) status from 1992 to 1998 were obtained and compared from 11 population-based cancer registries in the United States that participate in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.
Results: From 1992 to1998, the overall proportion of breast cancers that were ER-positive and PR-positive increased from 75.4% to 77.5% (P = .0002) and from 65.0% to 67.7% (P < .0001), respectively, continuing trends observed before 1992. These increases were limited to women 40 to 69 years of age. The proportions of ER-positive/PR-positive tumors increased from 56.7% to 62.3% (P = .0010) among 40- to 49-year-olds, from 58.0% to 63.2% (P = .0002) among 50- to 59-year-olds, and from 63.2% to 67.9% (P = .0020) among 60- to 69-year-olds.
Conclusion: From 1992 to 1998, the proportion of tumors that are hormone receptor–positive rose as the proportion of hormone receptor–negative tumors declined. Because the incidence rates of hormone receptor–negative tumors remained fairly constant over these years, the overall rise in breast cancer incidence rates in the United States seems to be primarily a result of the increase in the incidence of hormone receptor–positive tumors. Hormonal factors may account for this trend.
This study was supported in part by grant nos. T32 CA 09168 and R01 CA 85913 from the National Cancer Institute. The data set used for this analysis was provided by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (August 2000 submission).
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Saloustros and D. Mavroudis
Screening and Detection of Breast Cancer and Prostate Cancer
JAMA,
March 17, 2010;
303(11):
1032 - 1032.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G Morris, F. King, and M J. Kennedy
Cytotoxic chemotherapy for pregnancy-associated breast cancer: single institution case series
Journal of Oncology Pharmacy Practice,
December 1, 2009;
15(4):
241 - 247.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Gnant, P. Blaha, P. Dubsky, R. Exner, F. Fitzal, E. Sporn, P. Panhofer, A. Dal Borgo, S. Bigenzahn, G. Steger, et al.
Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Therapeutic Advances in Medical Oncology,
November 1, 2009;
1(3):
123 - 136.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Postlberger, C. Menzel, R. Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, et al.
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
N. Engl. J. Med.,
February 12, 2009;
360(7):
679 - 691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Marti, A. Guth, A. Naik, and K. L. Hiotis
Receptor Status and Ethnicity of Indigent Patients With Breast Cancer in New York City
Arch Surg,
December 1, 2008;
143(12):
1227 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Cummings, B. Ettinger, P. D. Delmas, P. Kenemans, V. Stathopoulos, P. Verweij, M. Mol-Arts, L. Kloosterboer, L. Mosca, C. Christiansen, et al.
The Effects of Tibolone in Older Postmenopausal Women
N. Engl. J. Med.,
August 14, 2008;
359(7):
697 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hadji, J. -J. Body, M. S. Aapro, A. Brufsky, R. E. Coleman, T. Guise, A. Lipton, and M. Tubiana-Hulin
Practical guidance for the management of aromatase inhibitor-associated bone loss
Ann. Onc.,
August 1, 2008;
19(8):
1407 - 1416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Krieger
Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections
Int. J. Epidemiol.,
June 1, 2008;
37(3):
627 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn
Tumor Receptor Imaging
J. Nucl. Med.,
June 1, 2008;
49(Suppl_2):
149S - 163S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Del Mastro, B. Dozin, E. Aitini, T. Catzeddu, E. Baldini, A. Contu, A. Durando, S. Danese, G. Cavazzini, G. Canavese, et al.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
Ann. Onc.,
February 1, 2008;
19(2):
299 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Cronin-Fenton, L. A. Ries, L. X. Clegg, and B. K. Edwards
Rising Incidence Rates of Breast Carcinoma With Micrometastatic Lymph Node Involvement
J Natl Cancer Inst,
July 4, 2007;
99(13):
1044 - 1049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Touillaud, A. C. M. Thiebaut, A. Fournier, M. Niravong, M.-C. Boutron-Ruault, and F. Clavel-Chapelon
Dietary Lignan Intake and Postmenopausal Breast Cancer Risk by Estrogen and Progesterone Receptor Status
J Natl Cancer Inst,
March 21, 2007;
99(6):
475 - 486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cho, W. Y. Chen, D. J. Hunter, M. J. Stampfer, G. A. Colditz, S. E. Hankinson, and W. C. Willett
Red meat intake and risk of breast cancer among premenopausal women.
Arch Intern Med,
November 13, 2006;
166(20):
2253 - 2259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, et al.
Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer
J. Clin. Oncol.,
June 20, 2006;
24(18):
2793 - 2799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Ring, I. E. Smith, A. Jones, C. Shannon, E. Galani, and P. A. Ellis
Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching Hospitals
J. Clin. Oncol.,
June 20, 2005;
23(18):
4192 - 4197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sweeney, C. K. Blair, K. E. Anderson, D. Lazovich, and A. R. Folsom
Risk Factors for Breast Cancer in Elderly Women
Am. J. Epidemiol.,
November 1, 2004;
160(9):
868 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Althuis, J. H. Fergenbaum, M. Garcia-Closas, L. A. Brinton, M. P. Madigan, and M. E. Sherman
Etiology of Hormone Receptor-Defined Breast Cancer: A Systematic Review of the Literature
Cancer Epidemiol. Biomarkers Prev.,
October 1, 2004;
13(10):
1558 - 1568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Monson, D. A. Litvak, and R. J. Bold
Surgery in the Aged Population: Surgical Oncology
Arch Surg,
October 1, 2003;
138(10):
1061 - 1067.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yamamoto, T. Sobue, M. Kobayashi, S. Sasaki, and S. Tsugane
Soy, Isoflavones, and Breast Cancer Risk in Japan
J Natl Cancer Inst,
June 18, 2003;
95(12):
906 - 913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A A Kubba
Breast cancer and the pill
J R Soc Med,
June 1, 2003;
96(6):
280 - 283.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Jordan
The Ups and Downs of the Estrogen Receptor
J. Clin. Oncol.,
January 1, 2003;
21(1):
3 - 4.
[Full Text]
[PDF]
|
|
|
|
